XM does not provide services to residents of the United States of America.
D
D

DerwentLondon

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Carnival, Natwest Group, Unite Group

EUROPE RESEARCH ROUNDUP- Carnival, Natwest Group, Unite Group Nov 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Carnival, Natwest Group and Unite Group, on Tuesday. HIGHLIGHTS * Antofagasta ANTO.L : Barclays raises target price to 2000p from 1500p * Carnival Plc CCL.L : Morgan Stanley raises target price to 1550p from 1250p * GSK GSK.L : Jefferies cuts to hold from buy; cuts target price to 1525p from 2000p * Natwest Group Plc
A
A
A
A
B
B
B
B
B
C
C
C
D
D
D
E
G
G
G
H
L
N
P
A
A
A
B
B
B
D
E
L
N
R

Derwent London Says Volumes Expected To Pick Up Into 2025

BRIEF-Derwent London Says Volumes Expected To Pick Up Into 2025 Nov 7 (Reuters) - Derwent London PLC DLN.L : DERWENT LONDON PLC - THIRD QUARTER BUSINESS UPDATE DERWENT LONDON PLC - THERE IS INCREASED INTEREST ACROSS INVESTMENT MARKET AND VOLUMES ARE EXPECTED TO PICK UP INTO 2025 DERWENT LONDON PLC - LOOKING AT AN INCREASING NUMBER OF ACQUISITION OP
D

Barratt Redrow, Genuit Group, Munich Re

EUROPE RESEARCH ROUNDUP-Barratt Redrow, Genuit Group, Munich Re Oct 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Barratt Redrow, Genuit Group and Munich Re, on Monday. HIGHLIGHTS * Barratt Redrow Plc BTRW.L : Morgan Stanley raises to overweight from equal-weight * Genuit Group Plc GENG.L : JP Morgan initiates coverage with neutral rating; PT 535p * Intertek ITRK.L : RBC cuts to sector perform from outperform * Munich Re MUVGn.
B
B
B
B
B
C
D
D
E
E
E
F
G
N
O
R
S
A
P

AstraZeneca, Danske Bank, Johnson Matthey

EUROPE RESEARCH ROUNDUP-AstraZeneca, Danske Bank, Johnson Matthey Oct 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Danske Bank and Johnson Matthey, on Thursday. HIGHLIGHTS * AstraZeneca AZN.L : Jefferies cuts target price to 11,400p from 11,700p * Baltic Classifieds Group Plc BCG.L : Berenberg raises target price to 360p from 300p * Danske Bank DANSKE.CO : JP Morgan cuts target price to DKK 185 from DKK 190 * John
A
B
D
G
K
N
P
P
R
R
S
S
T
V
V
J
N
P

Bureau Veritas, Covestro AG, Redcare Pharmacy NV

EUROPE RESEARCH ROUNDUP-Bureau Veritas, Covestro AG, Redcare Pharmacy NV Oct 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bureau Veritas, Covestro AG and Redcare Pharmacy NV, on Wednesday. HIGHLIGHTS * British Land BLND.L : Deutsche Bank raises to buy from hold * Bureau Veritas BVI.PA : JP Morgan cuts to neutral from overweight * Covestro AG 1COV.DE : Jefferies cuts to hold from buy * Redcare Pharmacy NV RDC.DE : HSBC raises t
A
A
A
B
B
B
D
E
E
E
E
E
E
E
F
G
I
M
M
A
A
A
A
B
B
E
G
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.